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ORIGINAL ARTICLE
Validation of a health-related quality of life
instrument for primary ciliary dyskinesia (QOL-PCD)
Laura Behan,1,2,3,4 Margaret W Leigh,5 Sharon D Dell,6,7,8,9 Audrey Dunn Galvin,4
Alexandra L Quittner,10 Jane S Lucas1,2,3
ABSTRACT
Background Quality of life (QOL)-primary ciliary
dyskinesia (PCD) is the ﬁrst disease-speciﬁc, health-
related QOL instrument for PCD. Psychometric validation
of QOL-PCD assesses the performance of this measure in
adults, including its reliability, validity and responsiveness
to change.
Methods Seventy-two adults (mean (range) age:
33 years (18–79 years); mean (range) FEV1% predicted:
68 (26–115)) with PCD completed the 49-item QOL-
PCD and generic QOL measures: Short-Form 36 Health
Survey, Sino-Nasal Outcome Test 20 (SNOT-20) and St
George Respiratory Questionnaire (SGRQ)-C. Thirty-ﬁve
participants repeated QOL-PCD 10–14 days later to
measure stability or reproducibility of the measure.
Results Multitrait analysis was used to evaluate how
the items loaded on 10 hypothesised scales: physical,
emotional, role and social functioning, treatment burden,
vitality, health perceptions, upper respiratory symptoms,
lower respiratory symptoms and ears and hearing
symptoms. This analysis of item-to-total correlations led
to 9 items being dropped; the validated measure now
comprises 40 items. Each scale had excellent internal
consistency (Cronbach’s α: 0.74 to 0.94). Two-week
test–retest demonstrated stability for all scales (intraclass
coefﬁcients 0.73 to 0.96). Signiﬁcant correlations were
obtained between QOL-PCD scores and age and FEV1.
Strong relationships were also found between QOL-PCD
scales and similar constructs on generic questionnaires,
for example, lower respiratory symptoms and SGRQ-C
(r=0.72, p<0.001), while weak correlations were found
between measures of different constructs.
Conclusions QOL-PCD has demonstrated good internal
consistency, test–retest reliability, convergent and
divergent validity. QOL-PCD offers a promising tool for
evaluating new therapies and for measuring symptoms,
functioning and QOL during routine care.
INTRODUCTION
Primary ciliary dyskinesia (PCD) is a rare, heteroge-
neous genetic disorder characterised by impaired
mucociliary clearance due to abnormal ciliary func-
tion. Individuals with PCD usually present with
unexplained neonatal respiratory symptoms in the
ﬁrst few days of life,1 2 have early onset of persist-
ent sinopulmonary infections, bronchiectasis during
childhood3 and a progressive decline in lung func-
tion.4 This can lead to end-stage lung disease with
a report that 25% of adult patients with PCD in
the USA required long-term oxygen or lung trans-
plantation.5 Male infertility is common since sperm
ﬂagella have a similar ultrastructure to cilia; the
incidence of female infertility and of ectopic preg-
nancy is unclear and is explained by immotile fallo-
pian tube cilia. Motile embryonic nodal cilia
contribute to left-right asymmetry and nearly half
of patients with PCD exhibit situs inversus, and
12% heterotaxy syndromes, sometimes associated
with complex congenital cardiac defects.6
Outcome measures that have been used to assess
disease severity in PCD include spirometry,4 chest
CT,3 7 MRI8 and lung clearance index.9–12 These
physiological and radiological measures all have
limitations in terms of their sensitivity or feasibility
to monitor disease progression. The Food and
Drug Administration (FDA) and the European
Medicines Agency strongly endorse the use of
outcome measures in clinical trials, assessing the
impact of the disease on the patient’s daily symp-
toms and functioning (eg, physical, respiratory,
social) in addition to physiological measures.13–15
Treatment strategies for PCD have necessarily been
applied from other diseases,16 17 particularly cystic
ﬁbrosis, since no medications have speciﬁcally been
tested and approved for PCD. A major obstacle to
evaluating new treatments and monitoring disease
progression is the lack of a disease-speciﬁc outcome
measure.18
Thus, we developed health-related quality of life
(HRQOL) measures to assess the impact of PCD
Key messages
What is the key question?
▸ This work evaluates the performance of the
ﬁrst health-related quality of life measure for
adults with primary ciliary dyskinesia
(QOL-PCD), to overcome the lack of a reliable
outcome measure in this illness.
What is the bottom line?
▸ Psychometric validation has shown that
QOL-PCD is a reliable and valid
patient-reported outcome measure for adults
with PCD.
Why read on?
▸ This work has led to the ﬁrst validated
health-related QOL instrument speciﬁc for PCD,
providing a promising outcome measure for use
in clinical trials and clinical practice.
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for children, teenagers and adults from the patient perspective.19
Here, we present the psychometric validation of the English
version of QOL-PCD in adults from the UK, the USA and
Canada.
METHODS
Participants
Participants were recruited from PCD diagnostic centres across
the UK, the USA and Canada. Adults (aged ≥18 years) with a
positive diagnosis of PCD were eligible to participate.
Information about the study was provided at a clinic appoint-
ment or by telephone. The following inclusion criteria had to
be met by patients: (1) diagnosis of PCD in one of the speciﬁed
diagnostic centres, (2) age ≥18 years and (3) ability to read and
speak English ﬂuently. The UK participants had been diagnosed
at one of the English diagnostic centres20 21 based on clinical
phenotype plus high-speed video analysis of ciliary function
and/or assessment of ciliary ultrastructure by electron micros-
copy. North American participants were diagnosed at a specia-
lised PCD research centre, based on: a compatible clinical
phenotype plus defect in ciliary ultrastructure and/or identiﬁca-
tion of biallelic disease-causing mutations in one of the PCD
genes.
QOL-PCD scales
The QOL-PCD adult version consisted of 49 items,19 which
were self-completed electronically at home or in the clinic,
where possible; ‘pen and paper’ copies were provided to those
without access to internet. Development of QOL-PCD followed
the procedures and analyses recommended by the FDA guidance
on patient-reported outcome measures.15 Previously reported
content validity, clinical relevance score and cognitive testing
conducted on interim versions supported QOL-PCD concepts,
items and scale options.19 Participants were provided with a
unique study number and a link to the online survey. No identi-
ﬁable information was included, and the data were captured on
a server of University of Southampton. Most responses used a
4-point Likert scale: ‘not at all true’ to ‘very true’ or ‘never’ to
‘always’. The ﬁrst time QOL-PCD was completed, participants
also completed generic questionnaires: Short-Form 36 Health
Survey (SF-36), the shortened St George Respiratory
Questionnaire (SGRQ-C) and a measure focusing on rhinosinus
symptoms: Sino-Nasal Outcome Test 20 (SNOT-20). Further
details on this protocol and these measures can be found in the
online supplementary data.
Statistical analysis
Statistical analyses were conducted using the SPSS Statistics for
Windows, V.21.0 (IBM, Armonk, New York, USA); p<0.05 was
considered to be statistically signiﬁcant.
To estimate the sample size needed to calculate internal con-
sistency, we used equations developed by Bonett22 to identify
sample sizes needed to establish Cronbach’s α. This formula
used parameters for precision, number of items and level of reli-
ability. For an average of ﬁve items per scale, a sample size of 59
yielded an α coefﬁcient of 0.70 with 95% CI.
We assessed the distribution of responses for each item and
each scale to look for ﬂoor and ceiling effects. We conducted
multitrait analysis to test the ﬁt between items and their
hypothesised versus competing scales. This type of analysis was
developed for smaller samples for which factor analysis is not
appropriate. These analyses assessed the extent to which items
correlated with their hypothesised versus competing scales; we
required item-to-scale correlations ≥0.40 with the intended
scale and lower correlations with competing scales.23–25 We con-
sidered ﬂoor and ceiling effects, using <15% of participants as
the threshold for the highest and lowest scores for a scale.26
Reliability
Internal consistency of the QOL-PCD scales were investigated
by Cronbach’s α values. Cronbach’s α gives a score of between
0 and 1, a value of >0.70 indicating good internal consistency.
Items were removed if this led to higher internal consistency (ie,
higher Cronbach’s α) to increase the parsimony and efﬁciency
of the instrument.27 28 The distributions of responses and multi-
trait analyses were reviewed in a series of teleconferences to
decide which items could be removed, allowing us to shorten
QOL-PCD, taking reliability and clinical relevance into
consideration.
Test–retest reliability was assessed using intraclass correlation
coefﬁcients (ICC) in stable patients who completed the
QOL-PCD a second time, 10–14 days after completing the base-
line measures. An ICC value of >0.60 provided evidence of
good stability and >0.75 excellent stability for each scale.
Validity
For a questionnaire to be construct valid, all items together
should represent the underlying construct (HRQOL). Construct
validity can be determined by testing the instrument against
hypotheses. We hypothesised a priori that clinical features (age,
gender, FEV1 and Pseudomonas status) would correlate with
speciﬁc scales (eg, FEV1 would correlate with physical function-
ing and upper respiratory symptoms (construct validity).
Cohen’s guidelines for the interpretation of correlation coefﬁ-
cients were used; correlations between 0.50 and 1.00 were
interpreted as strong, correlations between 0.30 and 0.50 as
moderate, correlations between 0.10 and 0.30 as small and cor-
relations <0.1 as weak.29 We also predicted that QOL-PCD
scales would have moderate correlations (>0.3), using
Spearman’s correlation, with generic scales (SF-36, SGRQ-C
and SNOT-20) measuring similar constructs (convergent valid-
ity). We hypothesised small or weak correlations (<0.3) with
scales measuring different constructs (divergent validity). Details
of the hypothesised correlations are provided in tables 4 and 5.
Distribution-based measures of clinical signiﬁcance
Minimal clinically important difference (MCID) in a HRQOL
score is deﬁned as ‘the smallest difference in score in the
domain of interest which patients perceive as beneﬁcial and
which would mandate, in the absence of troublesome side
effects and excessive cost, a change in the patient’s manage-
ment’.30 MCID can be determined using anchor-based and
distribution-based methods. Distribution-based methods rely on
the statistical distributions of HRQOL scores in a given study.
We applied two distribution-based methods in this study. These
were: (1) SDs of QOL-PCD scale mean scores were divided by
2 to establish a 1/2 SD change and (2) the SE of measurement
(SEM) was generated for all QOL-PCD scores using the follow-
ing formula: SD√(1−α) (SD=SD of mean baseline QOL-PCD
scale score and α=scale reliability).31 Wyrwich et al32 suggested
that a difference of 1 SEM frequently corresponds to a MCID.
Ethical approval
The study was approved by the National Research Ethics
Service, UK (UK 07/Q1702/109), the Research Ethics Board at
the Hospital for Sick Children in Toronto, Canada and the
Institutional Review Boards at the University of North Carolina,
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Chapel Hill. Written consent was obtained prior to
participation.
RESULTS
Participants
Between April 2014 and March 2016, 72 adults were recruited,
slightly more than that required to establish reliability.
Participant characteristics are shown in table 1. The 49-item
prototype took a mean time of 8 min (SD=5) to complete.
Development of scales
We used a multitrait analysis to generate 10 hypothesised scales:
physical, emotional, role and social functioning, treatment
burden, vitality, health perceptions, upper respiratory symptoms,
lower respiratory symptoms and ears and hearing symptoms.
Examination of the distribution of responses to items and the
multitrait analyses enabled us to shorten the questionnaire by
removing nine items which were redundant, not strongly
endorsed or did not correlate strongly with its designated scale
(see online supplementary table E1). The ﬁnal QOL-PCD
comprises 40 items on 10 scales, which were subjected to
further psychometric analysis (see online supplementary table
E2).
Analyses of the 40-item QOL-PCD conﬁrmed that all items
had strong correlations (≥0.63) with their intended scales. Few
ﬂoor and ceiling effects were observed with the exception of: (1)
ﬂoor effects on the social functioning scale (16.7% of respon-
dents had low scores) and (2) ceiling effects were found on the
physical functioning and ears and hearing scales, with 23.9% and
18.1% of respondents scoring the highest values, respectively.
Reliability: internal consistency and test–retest reliability
The QOL-PCD scales had moderate to strong internal consist-
ency (0.74 to 0.94). Thirty-ﬁve participants repeated QOL-PCD
after 10–14 days, providing evidence of stability across all scales
with ICC ranging from 0.73 to 0.96 (table 2).
Validity
We had hypothesised that older age groups would report worse
physical functioning, poorer vitality and more symptoms
(table 3). Mean physical functioning scores were signiﬁcantly
worse in those who were older; average scores for the age group
18–22 years was 88.21 (SD=15.81), decreasing to 49.33
(SD=34.88) in the age group >55 years (p<0.001). Lower
respiratory symptoms scores were highest in the youngest
(18–22 years; M=58.76 (SD=16.72) and oldest age groups
(>55 years (M=55.00 (SD=24.21)) and worst in the age group
37–55 years (M=36.30 SD=19.90). For patients with reported
Pseudomonas aeruginosa, lower mean scores were reported for
physical functioning and lower and upper respiratory symptoms;
however, these did not reach statistical signiﬁcance. For lung
function, physical functioning scores were signiﬁcantly lower in
those with poor lung function, however, no signiﬁcant associa-
tions were found on the upper and lower respiratory symptoms
scores.
As hypothesised, females reported signiﬁcantly worse lower
respiratory symptoms (p=0.004) (table 3). Although mean treat-
ment burden scores were higher in males, this did not reach stat-
istical signiﬁcance (p=0.052). There was also no signiﬁcant
difference found between males and females on the social func-
tioning scale (table 3).
Convergent validity was tested by examining correlations
between scales measuring similar constructs on the QOL-PCD
with other validated scales: SNOT-20 (upper airway), the SF-36
(generic health status) and the SGRQ-C (lower respiratory)
(table 4). As expected, strong associations were found between
the QOL-PCD upper respiratory symptoms and the SNOT-20
total score (r=0.60, p<0.01). Strong correlations were also
found between QOL-PCD lower respiratory symptoms and
SGRQ-C symptoms (r=0.69, p<0.001). On the SF-36, as
hypothesised we found strong correlations between physical
functioning and QOL-PCD physical scale (r=0.83, p<0.001),
role-physical and QOL-PCD role functioning (r=0.83,
p<0.001) and mental health with QOL-PCD emotional func-
tioning scale (r=0.73, p<0.001). In contrast, as hypothesised,
much weaker relationships were found between the QOL-PCD
scores and generic questionnaires that measured dissimilar con-
structs (divergent validity). For example, the ear and hearing
symptoms on the QOL-PCD correlated weakly with role func-
tioning (r=0.39, p<0.001) on the SF-36 (table 4). Similarly, the
QOL-PCD lower respiratory symptoms scale correlated more
strongly than the upper respiratory scale, which focused on
sinus symptoms, with SGRQ-C symptoms.
Table 1 Participant characteristics by country of residence
UK
N=34
USA and Canada
N=38
Female, n (%) 20 (58.8) 29 (76.3)
Age
Mean in years (SD) 34.8 (17.3) 31.0 (12.9)
Range 18–79 18–65
18–32 years, n (%) 22 (64.7) 24 (63.2)
33–55 years, n (%) 4 (11.8) 12 (31.6)
>55 years, n (%) 8 (23.5) 2 (2.6)
FEV1% predicted
Mean (SD) 72 (26) 66 (19)
Range 26–115 33–101
>80%, n (%) 12 (35) 8 (21)
Missing, n (%) 1 (3) 1 (3)
Past/current growth of Pseudomonas aeruginosa, n (%)
Missing, n (%) 11 (32) 23 (61)
2 (6) 1 (3)
Education, n (%)
Second level or less 11 (32) 8 (21)
Some college 4 (12) 7 (19)
College graduate/postgraduate 16 (47) 21 (55)
Missing 3 (9) 2 (5)
Working status, n (%)
Part-time or full-time employment 18 (52.9) 7 (18.4)
Full-time homemaker 1 (2.9) 13 (34.2)
Attending education courses outside
the home
7 (20.6) 6 (15.8)
Attending education courses inside
the home
0 (0) 3 (7.9)
Not working due to health 3 (8.8) 2 (5.3)
Not working for other reason 3 (8.8) 6 (15.8)
Retired 2 (5.9) 1 (2.6)
Ethnicity, n (%)
White 32 (94.1) 31 (81.6)
Black 0 (0) 0 (0)
Hispanic 0 (0) 2 (5.3)
Asian 0 (0) 2 (5.3)
Other 2 (5.9) 1 (2.6)
Missing 0 (0) 2 (5.3)
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Summary of distribution-based measures
The MCID was estimated from distribution analyses (table 5).
Using 0.5 SD of baseline scores, MCID estimates ranged from
3.2 point (lower respiratory symptoms) to 15.2 points (physical
functioning). Using SEM values derived from baseline scores,
values ranged from 6.4 (lower respiratory symptoms) to 15.0
points (social functioning).
DISCUSSION
We have shown that QOL-PCD (adult version) is a valid instru-
ment to measure HRQOL in patients with PCD. Psychometric
testing conﬁrmed our measure to be robust, reliable and valid.
QOL-PCD was developed in the UK and North America to
ensure cross-cultural equivalence in English-speaking coun-
tries.19 The QOL-PCD has already been translated into Danish,
Dutch, German (developed and linguistically validated for
Germany and Switzerland), Greek and French; translations are
progressing well in Turkish, Arabic, Spanish (European), Italian
and Spanish (Latin America). This international approach is
important for rare diseases since multinational clinical trials are
needed to recruit sufﬁcient patients.
Our study involved the recruitment of 72 patients with PCD
from centres in North America (n=38) and the UK (n=34). All
age groups were represented in the study, and participants had a
range of disease severity (FEV1% predicted: 26%–115%). This
collaborative effort allowed us to recruit sufﬁcient participants
with this rare disease. However, given the modest size of the
study population, we conducted a multitrait analysis to develop
the scales rather than an exploratory factor analysis (which
would require >200 patients), or more complex analysis such as
Rasche analysis (which would require >100 patients).33 The
multitrait analysis supported the conceptual foundations of 10
scales with 40 items and has been recommended for use in the
development of HRQOL measures, which are expected to have
correlations across domains (eg, increased respiratory symptoms
Table 2 Internal consistency of QOL-PCD scales measured by Cronbach’s α and test–retest reliability measured by ICC
QOL-PCD (adult) scales No. of items Mean (SD) of scales
Cronbach’s α
N=72
ICC (95% CI)
N=35
Physical functioning 5 70.51 (30.37) 0.94 0.94 (0.89 to 0.97)
Emotional functioning 5 73.68 (19.56) 0.83 0.91 (0.82 to 0.95)
Treatment functioning 4 60.80 (23.70) 0.75 0.92 (0.82 to 0.96)
Social functioning 3 38.11 (29.47) 0.74 0.73 (0.47 to 0.87)
Role functioning 4 64.23 (28.98) 0.86 0.94 (0.88 to 0.97)
Health perception 4 51.16 (26.32) 0.83 0.91 (0.82 to 0.95)
Vitality 3 53.76 (21.93) 0.79 0.88 (0.75 to 0.94)
Upper respiratory symptoms 4 45.83 (26.76) 0.83 0.91 (0.81 to 0.95)
Lower respiratory symptoms 6 47.30 (15.49) 0.83 0.92 (0.85 to 0.96)
Ear and hearing symptoms 2 61.81 (28.59) 0.79 0.96 (0.87 to 0.97)
Cronbach’s α >0.7 indicates good internal consistency. ICC >0.6 indicates good stability and >0.75 excellent stability of the scales.
ICC, intraclass coefficients; PCD, primary ciliary dyskinesia; QOL, quality of life.
Table 3 QOL-PCD scales mean scores and SDs for participant characteristics where we had hypothesised an association a priori
Physical functioning Social functioning Vitality Treatment burden
Upper respiratory
symptoms
Lower respiratory
symptoms
Gender
Male (n=23) – 43.96 (32.74) – 69.61 (19.75) – 58.70 (15.32)
Female (n=49) 35.37 (27.74) 57.62 (24.37) 43.20 (20.36)
p=0.284 p=0.052 p=0.004
Age
18–22 years (n=26) 88.21 (15.81) – 58.55 (20.50) – 46.47 (23.35) 58.76 (16.72)
23–36 years (n=21) 69.21 (29.63) 52.91 (20.20) 43.25 (30.80) 40.21 (19.63)
37–55 years (n=15) 56.88 (32.35) 46.66 (20.30) 42.22 (27.72) 36.30 (19.90)
>55 years (n=10) 49.33 (34.88) 48.88 (23.54) 55.00 (26.41) 55.00 (24.21)
p<0.001 p=0.355 p=0.655 p=0.001
Pseudomonas
Yes (n=34) 63.92 (33.43) – – – 43.63 (26.75) 44.12 (20.51)
No (n=35) 76.38 (26.78) 48.57 (27.08) 52.22 (21.86)
p=0.092 p=0.448 p=0.117
FEV1% predicted
<40 (n=11) 41.82 (30.12) – – – 59.09 (24.28) 44.44 (26.99)
≥40 to <60 (n=14) 63.81 (32.94) 45.83 (26.90) 42.86 (25.17)
≥60 to <75 (n=16) 77.33 (29.04) 41.67 (28.87) 48.88 (17.21)
≥75 (n=29) 80.46 (23.70) 43.68 (26.51) 51.92 (19.49)
p<0.02 p=0.364 p=0.563
PCD, primary ciliary dyskinesia; QOL, quality of life.
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are likely to lead to decreased physical functioning). QOL-PCD
had excellent item-to-total correlations and strong internal con-
sistency across all scales (Cronbach’s α 0.74 to 0.94). More
complex analysis including factor analysis and Rasche analysis
may be an option in future studies if we are able to recruit
larger sample sizes.
All scales were stable in an analysis of test–retest reliability
over 10–14 days. QOL-PCD correlated with generic HRQOL
measures (SF-36, SGRQ-C, SNOT-20). As expected, there were
stronger relationships between scales assessing similar rather
than dissimilar constructs. As hypothesised, physical functioning
scores were highest for those with FEV1>75%. However, FEV1
did not correlate with lower respiratory symptoms scales. FEV1
may be a poor measure for disease severity in patients with
PCD as demonstrated in studies showing normal spirometry in
individuals with PCD with substantial structural lung changes
on chest CT.3 We recommend investigation into the association
between QOL-PCD and other outcome measures assessing
disease severity in PCD, such as chest CT,3 7 MRI8 and lung
clearance index9–12 in the future.
Worsening QOL with age has previously been described in a
PCD study using generic measures34 and decreases with age were
also found in this study for both physical functioning and lower
respiratory symptoms. Interestingly, the lowest QOL-PCD score
in the upper and lower respiratory symptom scales were in our
age group 37–55 years, with scores increasing again in the age
group >55 years. Furthermore, the age group >55 years had sig-
niﬁcantly lower FEV1 compared with the younger age group
combined (p=0.019). This may reﬂect speciﬁc challenges for this
younger age group in comparison to those who are older, for
example, lack of time to ﬁt in treatments due to careers and fam-
ilies, or perhaps a survivor effect that is, those who have survived
to 55 years may have milder symptoms. This highlights the kind
of nuanced information that can be derived from HRQOL mea-
sures, reﬂecting the impact of disease management (ie, adherence
to prescribed treatments) and progression of disease. Caution
should be exercised in the interpretation of these ﬁndings where
there is a limited sample size in each age group.
By facilitating discussion on issues that are of importance to
patients, clinicians can focus attention on their patient’s percep-
tions of their illness, facilitating collaborative care and shared
medical decision-making. Moreover, patient’s perceptions of
improved functioning that are not reﬂected in other physio-
logical outcomes may be important factors in promoting adher-
ence to treatments.
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Table 5 Summary of distribution-based criteria to determine a
minimum clinical significant change using 0.5 SD of the mean and
SE of the measure (SEM) for each of the QOL-PCD scales
QOL-PCD (adult) scales 0.5 SD SEM
Physical 15.2 7.4
Emotional 4.1 8.1
Treatment 6.0 11.9
Social 7.5 15.0
Role 5.4 10.8
Health perception 5.5 10.9
Vitality 3.8 7.6
Upper respiratory 5.5 11.0
Lower respiratory 3.2 6.4
Ears and hearing 6.6 13.1
PCD, primary ciliary dyskinesia; QOL, quality of life.
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QOL-PCD has also been developed for children (aged
6–12 years), adolescents (aged 13–17 years) and for parents
(proxy) of children aged 6–12 years. QOL-PCD has been trans-
lated into six conceptually and linguistically equivalent language
versions; a number of further translations are in progress, each
following a protocol-led process of forward and back translation
followed by cognitive testing. Validation of the remaining age-
speciﬁc tools and different languages is underway.
We had planned to measure responsiveness in this study.
Participants who contacted the study team towards the start of a
respiratory exacerbation were asked to complete the question-
naire during a respiratory exacerbation. However, only 10 parti-
cipants reported an exacerbation within the relatively short study
period, and time periods from the well to the ill states varied
considerable between patients (median of 54 days, range 3–
152 days). Despite the small numbers of patients who completed
QOL-PCD during an exacerbation (n=10), most scales evi-
denced worse mean scores in comparison to these patients’ stable
state. Scores for three subscales did not change during exacerba-
tions (ears and hearing symptoms, social and emotional function-
ing) (ﬁgure 1) perhaps suggesting that chest exacerbations have
minimal effects on these domains of functioning. Statistically
signiﬁcant results were also found (see online supplementary
table E3); however, these were difﬁcult to interpret given the
small numbers. QOL-PCD is now being used in a randomised
controlled study of azithromycin prophylaxis in PCD;35 we aim
to assess the responsiveness to treatment in this study.
The adult version of QOL-PCD is ready for use in clinical
trials to assess the beneﬁts of medications or non-
pharmacological interventions. It can also be used to understand
the natural course and progression of the disease in terms of its
effects on physical, emotional, role and social functioning. We
also propose QOL-PCD as a tool to be used at annual assess-
ments, providing a broad assessment of well-being, as perceived
by the patient.
Before QOL-PCD can effectively be used to assess interven-
tion studies, it is important to determine the MCID score to
allow for interpretation of changes in scores. We conducted pre-
liminary analysis to estimate the MCID through distribution
methods. This method is considered only supportive of an
MCID with an intervention required to produce an accurate
determination of change. QOL-PCD is currently being included
in the ﬁrst randomised clinical trial for PCD. This will facilitate
the MCID for each scale to be determined.
Figure 1 Difference in quality of
life-primary ciliary dyskinesia between
a stable baseline and a day during an
exacerbation. (A) Lower respiratory
symptoms scores. (B) Physical
functioning (n=10).
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In summary, we have developed19 and validated the ﬁrst
HRQOL instrument speciﬁc for PCD. QOL-PCD is valid and
reliable; it is short and easy for patients to complete and pro-
vides a promising outcome measure for use in clinical trials and
clinical practice.
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